56
Views
7
CrossRef citations to date
0
Altmetric
Review

Optimizing the use of patient data to improve outcomes for patients: narcotics for chronic noncancer pain

&
Pages 171-179 | Published online: 09 Jan 2014

References

  • Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain138(3), 507–513 (2008).
  • Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain109(3), 514–519 (2004).
  • Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA299(1), 70–78 (2008).
  • Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: the TROUP study. Pain138(2), 440–449 (2008).
  • Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ174(11), 1589–1594 (2006).
  • Raja SN, Haythornthwaite JA, Pappagallo M et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology59(7), 1015–1021 (2002).
  • Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine23(23), 2591–2600 (1998).
  • Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. Eur. J. Pain11(5), 490–518 (2007).
  • Djulbegovic B, Lacevic M, Cantor A et al. The uncertainty principle and industry-sponsored research. Lancet356(9230), 635–638 (2000).
  • Montori VM, Jaeschke R, Schünemann HJ et al. Users’ guide to detecting misleading claims in clinical research reports. BMJ329(7474), 1093–1096 (2004).
  • Turk DC, Dworkin RH, Revicki D et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain137(2), 276–285 (2008).
  • Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J. Pain9(2), 105–121 (2008).
  • Guyatt G, Montori V, Devereaux PJ et al. Patients at the center: in our practice, and in our use of language. ACP J. Club140(1), A11–A12 (2004).
  • Berger M, Muhlhauser I. Diabetes care and patient-oriented outcomes. JAMA281(18), 1676–1678 (1999).
  • Sweeney KG, MacAuley D, Gray DP. Personal significance: the third dimension. Lancet351(9096), 134–136 (1998).
  • Turk DC, Dworkin RH, McDermott MP et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain139(3), 485–493 (2008).
  • Turner JA, Franklin G, Heagerty PJ et al. The association between pain and disability. Pain112(3), 307–314 (2004).
  • Côté P, Hogg-Johnson S, Cassidy JD, Carroll L, Frank JW. The association between neck pain intensity, physical functioning, depressive symptomatology and time-to-claim-closure after whiplash. J. Clin. Epidemiol.54(3), 275–286 (2001).
  • Cassidy JD, Carroll L, Côté P, Berglund A, Nygren A. Low back pain after traffic collisions: a population-based cohort study. Spine28(10), 1002–1009 (2003).
  • Cassidy JD, Carroll LJ, Côté P, Lemstra M, Berglund A, Nygren A. Effect of eliminating compensation for pain and suffering on the outcome of insurance claims for whiplash injury. N. Engl. J. Med.342(16), 1179–1186 (2000).
  • Schofferman J. Restoration of function: the missing link in pain medicine? Pain Med.7(Suppl. 1), S159–S165 (2006).
  • Caldwell JR, Rapoport RJ, Davis JC et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J. Pain Symptom Manage.23(4), 278–291 (2002).
  • Harati Y, Gooch C, Swenson M et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology50(6), 1842–1846 (1998).
  • Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N; Protocol TRP-CAN-1 Study Group. Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J. Rheumatol.31(12), 2454–2463 (2004).
  • Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G; MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain – results of a double-blind placebo-controlled trial (MONTAS). Pain97(3), 223–233 (2002).
  • Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain105(1–2), 71–78 (2003).
  • Pavelka K, Peliskova Z, Stehlikova H et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin. Drug Invest.16(6), 421–429 (1998).
  • Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am. J. Med.92(2), 121–124 (1992).
  • Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann. Intern. Med.117(11), 916–921 (1992).
  • Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians’ willingness to prescribe. Lancet343(8907), 1209–1211 (1994).
  • Jaeschke R, Guyatt G, Shannon H, Walter S, Cook D, Heddle N. Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association. CMAJ152(3), 351–357 (1995).
  • Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ310(6977), 452–454 (1995).
  • Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB. Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J. Clin Epidemiol.55(9), 888–892 (2002).
  • Nexoe J, Gyrd-Hansen D, Kragstrup J, Kristiansen IS, Nielsen JB. Danish GPs’ perception of disease risk and benefit of prevention. Fam. Pract.19(1), 3–6 (2002).
  • Gigerenzer G. The psychology of good judgment: frequency formats and simple algorithms. Med. Decis. Making16(3), 273–280 (1996).
  • Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ327(7417), 741–744 (2003).
  • Hoffrage U, Gigerenzer G. Using natural frequencies to improve diagnostic inferences. Acad. Med.73(5), 538–540 (1998).
  • Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum.43(7), 1478–1487 (2000).
  • Kulkarni AV. Distribution-based and anchor-based approaches provided different interpretability estimates for the Hydrocephalus Outcome Questionnaire. J. Clin. Epidemiol.59(2), 176–184 (2006).
  • Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J. Clin. Epidemiol.59, 374–380 (2006).
  • Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control. Clin. Trials10(4), 407–415 (1989).
  • Deyo RA, Inui TS. Toward clinical applications of health status measures: sensitivity of scales to clinically important changes. Health Serv. Res.19(3), 275–289 (1984).
  • Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED Jr. The cost effectiveness of auranofin: results of a randomized clinical trial. J. Rheumatol.15(1), 35–42 (1988).
  • Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ325(7365), 652–654 (2002).
  • Furukawa T. From effect size into number needed to treat. Lancet353(9165), 1680 (1999).
  • Brooks WB, Jordan JS, Divine GW, Smith KS, Neelon FA. The impact of psychologic factors on measurement of functional status. Assessment of the sickness impact profile. Med. Care28(9), 793–804 (1990).
  • Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet2(8601), 4–8 (1988).
  • King TK, Ali N, Briscoe WA. Treatment of hypoxia with 24 percent oxygen. A new approach to the interpretation of data collected in a pulmonary intensive care unit. Am. Rev. Respir. Dis.108(1), 19–29 (1973).
  • Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care19(8), 787–805 (1981).
  • Ware JE Jr, Manning WG Jr, Duan N, Wells KB, Newhouse JP. Health status and the use of outpatient mental health services. Am. Psychol.39(10), 1090–1100 (1984).
  • Brook RH, Ware JE Jr, Rogers WH et al. Does free care improve adults’ health? Results from a randomized controlled trial. N. Engl. J. Med.309(23), 1426–1434 (1983).
  • Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann. Emerg. Med.27(4), 485–489 (1996).
  • Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J. Pain8(4), 283–291 (2004).
  • Lauridsen HH, Hartvigsen J, Manniche C, Korsholm L, Grunnet-Nilsson N. Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients. BMC Musculoskelet. Disord.7, 82 (2006).
  • Kovacs FM, Abraira V, Royuela A et al. Minimal clinically important change for pain intensity and disability in patients with nonspecific low back pain. Spine32(25), 2915–2920 (2007).
  • Ostelo RW, Deyo RA, Stratford P et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine33(1), 90–94 (2008).
  • Ruoff GE, Rosenthal N, Jordan D et al; Protocol CAPSS-112 Study Group. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin. Ther.25(4), 1123–1141 (2003).
  • Jordan K, Dunn KM, Lewis M, Croft P. A minimal clinically important difference was derived for the Roland-Morris Disability Questionnaire for low back pain. J. Clin. Epidemiol.59(1), 45–52 (2006).
  • Guyatt GH, Juniper EF, Walter SD et al. Interpreting treatment effects in randomised trials. BMJ316(7132), 690–693 (1998).
  • Derose K, Kanouse D, Weidmer B et al. Developing a Spanish-language sample report for CAHPS. Jt Comm. J. Qual. Patient Saf.33(11), 681–688 (2007).
  • Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care41(5), 582–592 (2003).
  • Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med. Care39(10), 1039–1047 (2001).
  • Supina AL, Feeny DH, Carroll LJ, Johnson JA. Misinterpretation with norm-based scoring of health status in adults with type 1 diabetes. Health Qual. Life Outcomes4, 15–23 (2006).
  • Guyatt G, Hayward R, Richardson WS et al. Moving from evidence to action. In: The Users’ Guides to the Medical Literature: a Manual for Evidence-Based Clinical Practice. Guyatt G, Drummond R (Eds). AMA Publications, IL, USA (2002).
  • Oxman A, Guyatt G, Cook D, Montori V. Summarizing the evidence. In: The Users’ Guides to the Medical Literature: a Manual for Evidence-Based Clinical Practice. Guyatt G, Drummond R (Eds). AMA Publications, IL, USA (2002).
  • Cohen J. Statistical Power Analysis in the Behavioral Sciences (2nd Edition). Lawrence Erlbaum Associates, NJ, USA (1988).
  • Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet348(9035), 1115–1119 (1996).
  • Glowinski J, Boccard E. Placebo-controlled study of the analgesic efficacy of a paracetamol 500 mg/codeine 30 mg combination together with low-dose vs high-dose diclofenac in rheumatoid arthritis. Clin. Drug Invest.18(3), 189–197 (1999).
  • Gobel H, Stadler TH. Treatment of pain due to postherpetic neuralgia with tramadol: results of an open, parallel pilot study vs clomipramine with and without levomepromazine. Clin. Drug Invest.10(4), 208–214 (1995).
  • Parr G, Darekar B, Fletcher A et al. Joint pain and quality of life: results of a randomised trial. Br. J. Clin. Pharmacol.27, 235–242 (1989).
  • Salzman RT, Brobyn RD. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis. Pharmacology27(Suppl. 1), 55–64 (1983).
  • Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Cont. Clin. Trials17(1), 1–12 (1996).
  • Berger VW. Is the Jadad score the proper evaluation of trials? J. Rheumatol.33(8), 1710–1712 (2006).
  • Atkins D, Best D, Briss PA et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ328(7454), 1490–1497 (2004).
  • Guyatt G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest129(1), 174–181 (2006).
  • Ballantyne JC, Mao J. Opioid therapy for chronic pain. N. Engl. J. Med.349(20), 1943–1953 (2003).
  • Clarke KA, Iphofen R. A phenomenological hermeneutic study into unseen chronic pain. Br. J. Nurs.17(10), 658–663 (2008).
  • College of Physicians and Surgeons of Ontario. Evidence-Based Recommendations for Medical Management of Chronic Non-Malignant Pain: Reference Guide for Physicians. College of Physicians and Surgeons of Ontario, Toronto, ON, Canada (2000).
  • Chronic Pain Initiative. Report of the Chronic Pain Expert Advisory Panel. Ontario Workplace Safety and Insurance Board, Toronto, ON, Canada (2000).
  • Von Korff M, Deyo RA. Potent opioids for chronic musculoskeletal pain: flying blind? Pain109(3), 207–209 (2004).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.